Track topics on Twitter Track topics that are important to you
Lemtrada (alemtuzumab) is being developed by Sanofi (Genzyme) in collaboration with Bayer Healthcare for the treatment of relapsing multiple sclerosis. The Sanofi subsidiary said it will "soon" launch both Lemtrada and Aubagio® (teriflunomide) in the EU region. While Genzyme holds worldwide rights to Lemtrada, and has primary responsibility for its development and commercialization in MS, Bayer HealthCare retains an option to co-promote the drug in MS, and has told Genzyme of its intention to co-promote under this option. Bayer would receive contingent payments based on sales revenue, following regulatory approval and commercialization.
Lemtrada was developed to treat certain types of leukaemia and lymphoma (cancers of the immune system).
It binds to and kills white blood cells (immune cells) thereby stopping the immune cells from entering the brain and attacking myelin (which is the cause of damage in MS).
Lemtrada (Alemtuzumab) is a monoclonal antibody that selectively targets CD52, a protein abundant on T and B cells. Alemtuzumab binds to an antigen called CD52 which is found on the surface of certain T-cells, a type of lymphocyte involved in the MS immune response, and kills the T-cell.
This monoclonal antibody was licensed to treat a type of leukaemia (under the brandname MabCampath).